Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
Identifieur interne : 001428 ( Main/Exploration ); précédent : 001427; suivant : 001429Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
Auteurs : Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-05.
English descriptors
Abstract
Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease (PD), there are significant limitations to its chronic use. Growing preclinical and clinical evidence suggests that the severity of motor fluctuations is influenced both by PD severity and pulsatile stimulation of striatal dopamine receptors. Current management of motor fluctuations is based primarily on strategies to prolong the effects of dopaminergic stimulation. This prolongation is accomplished either through the use of long‐acting dopaminergic drugs or prolonging of the effects of levodopa. During the past decade, the armamentarium of dopamine agonists increased and agents that prolong the plasma half‐life of levodopa became available. Furthermore, recent clinical trials provide evidence‐based approaches to improve the management of motor fluctuations in patients with advanced and early PD. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20461
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L." last="Widnell">Katherine L. Widnell</name></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20461</idno><idno type="url">https://api.istex.fr/document/0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000C69</idno><idno type="wicri:Area/Main/Curation">000B15</idno><idno type="wicri:Area/Main/Exploration">001428</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L." last="Widnell">Katherine L. Widnell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">S11</biblScope><biblScope unit="supplement">11</biblScope><biblScope unit="page" from="S30">S30</biblScope><biblScope unit="page" to="S37">S37</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607</idno><idno type="DOI">10.1002/mds.20461</idno><idno type="ArticleID">MDS20461</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COMT inhibition</term><term>Parkinson's disease</term><term>dopamine agonist</term><term>levodopa</term><term>motor fluctuations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease (PD), there are significant limitations to its chronic use. Growing preclinical and clinical evidence suggests that the severity of motor fluctuations is influenced both by PD severity and pulsatile stimulation of striatal dopamine receptors. Current management of motor fluctuations is based primarily on strategies to prolong the effects of dopaminergic stimulation. This prolongation is accomplished either through the use of long‐acting dopaminergic drugs or prolonging of the effects of levodopa. During the past decade, the armamentarium of dopamine agonists increased and agents that prolong the plasma half‐life of levodopa became available. Furthermore, recent clinical trials provide evidence‐based approaches to improve the management of motor fluctuations in patients with advanced and early PD. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li><li>Wisconsin</li></region></list><tree><country name="États-Unis"><region name="Wisconsin"><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L." last="Widnell">Katherine L. Widnell</name></region><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001428 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001428 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607
|texte= Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
}}
| This area was generated with Dilib version V0.6.23. |  |